Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from argenx

Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again

Shares of Dianthus Therapeutics surged Monday after the company's autoimmune disease treatment succeeded in a midstage study.

Investors Business Daily

3 Healthcare Pathbreakers With Long-Term Tailwinds

These three firms in the fast-changing healthcare sector stand out to analysts for their strong product lineups, defensible technology, and notable pipelines.

MarketBeat

Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded

Argenx saw its IBD SmartSelect Composite Rating rise to 96 Tuesday, up from 94 the day before.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Argenx Tops Buy Point On Bullish Study, 850 Price Target

Argenx announced positive study results and plans to seek FDA approval to expand its label for Vyvgart.

Investors Business Daily

Argenx Targets FDA Label Expansion After Vyvgart Trial Success

Argenx SE (NASDAQ:ARGX) released topline data on Monday from the pivotal Phase 3 ADAPT SERON study of Vyvgart (IV: efgartigimod alfa-fcab).

Benzinga

Monica Seles Myasthenia Gravis Bombshell: What Is the Rare Disease and Is It Linked to Her 1993 On-Court Stabbing?

Monica Seles reveals she has myasthenia gravis and raises awareness ahead of the U.S. Open, sparking questions about her 1993 on-court stabbing.

International Business Times UK

Argenx Beats Sales Expectations — But Not By Enough — And Shares Tumble

Argenx stock tumbled Thursday after the company's autoimmune disease drug, Vyvgart, beat first-quarter sales forecasts — but not by enough.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Argenx Stock Extends Rally In A Base As Earnings Loom

Argenx stock is rising Wednesday as the major indexes sell off. The autoimmune disease treatment stock is climbing in an early-stage base.

Investors Business Daily

Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug

Argenx stock jumped Friday after the FDA cleared its autoimmune disease drug, Vyvgart Hytrulo, for at-home treatment.

Investors Business Daily

Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity

Biohaven stock tumbled for the second day running Tuesday after its bipolar mania treatment failed in a three-week study.

Investors Business Daily

Argenx Vaults 3,659% With Profit Growth Seen In Triple Digits; Earnings Next As Stock Hits Highs

Argenx recently hit an all-time high ahead of fourth-quarter earnings. Shares are in a flat base with a buy point of 678.21.

Investors Business Daily

Biotech Leader Argenx In Buy Zone, Poised To Hit New Highs

Argenx stock is in a buy zone on the stock market today after a recent breakout and the biotech leader is poised to hit new highs.

Investors Business Daily

Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases

Argenx stock surged Wednesday after Amgen presented "underwhelming" results for a potential competitor to Vyvgart in an autoimmune disease.

Investors Business Daily

Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval

Argenx stock surged Monday after the FDA approved its drug, Vyvgart Hytrulo, for patients with an autoimmune condition known as CIDP.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay

Immunovant stock slumped Thursday — reversing a day-earlier jump — after pivoting its focus to what one analyst called "a backup compound."

Investors Business Daily

Biohaven Tumbles After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump

Biohaven stock tumbled Wednesday after the company's experimental protein-degrading drug lagged investor expectations.

Investors Business Daily

Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results

Biotech stocks Argenx and Immunovant surged Thursday — and Tourmaline fell — on a rival's lackluster muscle disease drug study.

StockNews.com

Top Biotech 3 Stocks With Accelerating Profits

The biotechnology industry is booming thanks to growing demand for innovative healthcare solutions, favorable government initiatives, and several scientific breakthroughs. Thus, quality biotech stocks Genmab (GMAB), Halozyme Therapeutics (HALO), and Vertex Pharmaceuticals (VRTX) could be ideal buys for substantial profits. Read more….

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Argenx Crashes 25% As The Setbacks Mount For Its Hallmark Drug, Vyvgart

Argenx stock crashed early Wednesday after its treatment for an autoimmune disease that causes skin blisters flopped in a Phase 3 study.

Investors Business Daily

Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review

The Dow Jones pushed higher, but the Nasdaq slipped despite strong software earnings and a Fed shift toward rate cuts. Tesla Cybertruck deliveries began.

Investors Business Daily

Argenx Stock Crashes On An Unexpected Failure For Its Biggest Drug

Argenx stock plummeted Tuesday after the company's drug unexpectedly failed to help patients with a rare blood disorder.

Investors Business Daily

Argenx Posts Strong Results For 'Seventh Straight Quarter Of Outperformance'

Argenx put up another strong quarter for immunology drug Vyvgart on Tuesday, but the biotech stock pulled back from bullish gains.

Investors Business Daily

Biohaven, Yet Another Rival To Argenx In Autoimmune Drugs, Just Rocketed 33%

Biohaven could rival Argenx and Immunovant after unveiling results Wednesday for an autoimmune diseases drug. BHVN stock rocketed.

Investors Business Daily

Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering

Immunovant stock reversed lower Wednesday after the company announced a $300 million offering. IMVT stock almost doubled Tuesday.

Investors Business Daily

Immunovant Doubles — And Slugs Argenx — As Autoimmune Disease Battle Heats Up

Immunovant said Tuesday its experimental drug lowered an antibody tied to autoimmune diseases and IMVT stock launched.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Investor Business Daily

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.